LD50 and LD90 doses of Cry1AcF was determined by using probit analysis in SPSS v. 21 software (IBM Corp., Armonk, NY, USA). Data of different bioassay (THC and PO assay data were checked for normality using Shapiro–Wilk test) and qPCR experiments was subjected to one-way ANOVA followed by Tukey’s honest significant difference (HSD) test (for multiple comparison among different treatments) in SAS v. 14.1 software (SAS, Inc. Cary, NC, USA).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.